Macrophage Reprogramming: Emerging Molecular Therapeutic Strategies for Nephrolithiasis
Biomolecules · 28.07.2025 · 15 (8) · 1090
DOI: 10.3390/biom15081090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 28.07.2025. Verfasst von Meng Shu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Changhai Hospital of Shanghai, Naval Medical University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Macrophages, Nephrolithiasis, Cellular Reprogramming. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xu Gao, National Key Research and Development Program of China.
Abstract (Originalsprache)
Nephrolithiasis, predominantly driven by calcium oxalate (CaOx) crystal deposition, poses a significant global health burden due to its high prevalence and recurrence rates and limited preventive/therapeutic options. Recent research has underscored a pivotal role for macrophage polarization in nephrolithiasis pathogenesis. Pro-inflammatory phenotype macrophages exacerbate crystal-induced injury and foster stone formation by amplifying crystal adhesion via an NF-κB–IL-1β positive-feedback axis that sustains ROS generation and NLRP3 inflammasome activation, whereas anti-inflammatory phenotype macrophages facilitate crystal clearance and tissue repair. We have summarized the research on treating nephrolithiasis and related renal injury by targeting macrophage polarization in recent years, including therapeutic approaches through pharmacological methods, epigenetic regulation, and advanced biomaterials. At the same time, we have critically evaluated the novel therapeutic strategies for macrophage reprogramming and explored the future development directions of targeting macrophage reprogramming for nephrolithiasis treatment, such as using single-cell/spatial omics to reveal the heterogeneity of macrophages in the stone microenvironment, chimeric antigen receptor macrophages (CAR-Ms) as a potential therapy for specific crystal phagocytosis in certain areas, and multi-omics integration to address inter-patient immune differences. This review highlights that macrophage reprogramming is a transformative frontier in nephrolithiasis management and underscores the need for further research to translate these molecular insights into effective clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Changhai Hospital of Shanghai, Naval Medical University, Shanghai 200433, China.
- Shanghai Key Laboratory of Cell Engineering, Shanghai 200433, China.
ORCID-Profile: Meng Shu
Förderung
- Xu Gao
- National Key Research and Development Program of China
Zitieren
APA
Shu, M., Jia, Y., Zhang, S., Zou, B., Ying, Z., Gao, X., Fang, Z., & Gao, X. (2025). Macrophage Reprogramming: Emerging Molecular Therapeutic Strategies for Nephrolithiasis. Biomolecules, 15(8), 1090. https://doi.org/10.3390/biom15081090
Vancouver
Shu M, Jia Y, Zhang S, Zou B, Ying Z, Gao X, et al. Macrophage Reprogramming: Emerging Molecular Therapeutic Strategies for Nephrolithiasis. Biomolecules. 2025;15(8):1090. doi:10.3390/biom15081090
BibTeX
@article{Shu2025,
author = {Shu, Meng and Jia, Yiying and Zhang, Shuwei and Zou, Bangyu and Ying, Zhaoxin and Gao, Xu and Fang, Ziyu and Gao, Xiaofeng},
title = {Macrophage Reprogramming: Emerging Molecular Therapeutic Strategies for Nephrolithiasis},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {8},
pages = {1090},
doi = {10.3390/biom15081090}
}
EUVIMED